At Janssen, we are passionate about transforming care for people living with pulmonary hypertension (PH). Hear our regional leaders discuss our commitment to PH. #PulmonaryHypertension
The Janssen Pharmaceutical Companies of Johnson & Johnson’s Post
More Relevant Posts
-
Stop by #CRT2024 March 11th to learn more about the Aria CV Pulmonary Hypertension System and early results from the ASPIRE PH Trial. We look forward to connecting with you. #Ariacv #pulmonaryhypertension #rightheartdysfunction
To view or add a comment, sign in
-
-
Foundation For Sarcoidosis Research joins our partner Pulmonary Hypertension Association is celebrating #WorldPHDay2024. Pulmonary Hypertension can be associated with advanced #sarcoidosis. Read the WASOG Conference 2023 statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension supported in part by FSR. https://lnkd.in/gcXB62wE
To view or add a comment, sign in
-
-
Did you know that pulmonary hypertension (PH) is often misdiagnosed? At Johnson & Johnson, we are focused on our goals of shortening time from diagnosis to treatment and helping to ensure access to the right therapy at the right time. #JNJPulmonaryHypertension #PulmonaryHypertension
To view or add a comment, sign in
-
-
In pulmonary arterial hypertension (PAH), oral treprostinil and selexipag have similar efficacy and safety profiles. https://brnw.ch/21wGHyb
To view or add a comment, sign in
-
-
Pulmonary arterial hypertension (PAH) is a rare but serious complication of scleroderma affecting lung arteries. Early detection is crucial for effective management. Consider supporting The Mo Experience by purchasing our merchandise and artworks at www.themoexperience.org. #Scleroderma #SclerodermaAwareness #SclerodermaWarrior #PAH #SclerodermaFacts
To view or add a comment, sign in
-
-
Explore the groundbreaking hypertension research led by Prof Lebo Gafane-Matemane, Associate Professor at NWU’s Hypertension in Africa Research Team (HART). In this enlightening video, she explores the critical role of kidneys in the development of hypertension and cardiovascular disease, unveiling findings from her extensive research. From the PURE study to SABPA and the African-PREDICT study, she shares key insights that underscore the urgency of addressing cardiovascular health globally. Watch: https://brnw.ch/21wJgTo #MyNWU #NWUInnovation #20YearsofGreatness
Dive into the Role of Kidneys in Hypertension with Prof Lebo Gafane-Matemane
https://www.youtube.com/
To view or add a comment, sign in
-
Competent and efficient Registered Clinical physiologist (cardiology) AHCS, member of PASCAR, cardiovascular sonographer, RCS, BLS, ACLS..
Severely elevated RVSP: right ventricular systolic pressure ( TR pressure gradient + Right atrial pressure of > 60 mmHg) could be strongly indicative of severe Pulmonary hypertension. Other features including classical D-shaped ventricle with systolic collapse of the septum into the LV due to increased systolic pressure in the RV. Elevated RVSP is mostly caused by elevated pressures in the pulmonary arteries 👍 features of Cor pulmonae (Markedly Dilated right ventricle and atrium). The systolic function of the right ventricle is reduced. Flattened inventricular septum mostly due to the pressure overload. Thickened LV cardiac walls, small LV cavity size, left ventricular concentric remodeling. Dilated and non-collapsible IVC. Severe TR functional due to dilated Tricuspid annulus. Dilated coronary sinus possibly due to the severe TR.
Obvious flattening of the septum. Severe pulmonary hypertension. Severely dilated RA with systolic hepatic reversal.
To view or add a comment, sign in
-
Why do people with Scleroderma need to know about PAH? About 1 in 10 people with Scleroderma will develop Pulmonary Arterial Hypertension (PAH) in their lifetime. Learn more about PAH and the simple, non-invasive blood test now funded by the Government for people with Scleroderma here. Learn more: https://lnkd.in/emgDpNdP #PulmonaryArterialHypertension #PAH
To view or add a comment, sign in
-
The European Society of Hypertension Annual Conference is underway in Berlin! Sharing the latest advances in innovation and research at conferences like ESH is crucial to addressing unmet needs and driving progress in hypertension. Resistant and uncontrolled hypertension are significant contributors to cardiovascular and renal complications that affect millions of people worldwide. The limitations of current treatment options mean there is an urgent need for alternatives to improve outcomes. Aldosterone is an important driver of hypertension and cardiorenal outcomes. Read more about aldosterone and the work we are doing to uncover novel approaches to slowing disease progression in hypertension here: https://lnkd.in/eRH38DA3 #ESH2024 #Hypertension #ClinicalInnovation #WhatScienceCanDo
To view or add a comment, sign in
-
-
I want to highlight an article on PH and how open dialogues lay the foundation for successful management of life-altering ailments. The critical role that adherence to prescribed medications plays, highlighting the significance of consistency and the role it plays in the battle against these health challenges. Open conversations are the bridge that brings patients and healthcare professionals together, and it's on this bridge that the future of health is built. Patients become not just recipients of healthcare but active participants in their own wellness journey. #medicationadherence Read the link to the manuscript in the comments.
At Janssen, we are committed to bringing #PassionAdvancementHope to people living with pulmonary hypertension (PH). This PH Awareness Month, we are excited to show our unwavering support for the PH community. Stay tuned! #LivePHearlessly #PHAwarenessMonth
To view or add a comment, sign in
-